Cogent Biosciences (COGT) Research & Development (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Research & Development data on file, last reported at $75.4 million in Q1 2026.

• On a quarterly basis, Research & Development rose 19.57% year-over-year to $75.4 million in Q1 2026; TTM through Mar 2026 was $282.1 million, a 16.11% increase from a year earlier, with the FY2025 full-year figure at $269.8 million, up 15.96% from the prior year.
• Research & Development for Q1 2026 stood at $75.4 million, roughly flat from $75.6 million in the prior quarter.
• Over the last five years, Research & Development for COGT reached as high as $75.6 million in Q4 2025 and fell as low as $25.5 million in Q1 2022.
• Historically, Research & Development has averaged $51.4 million across 5 years, with a median of $52.7 million in 2024.
• Across the five-year window, Research & Development jumped 210.12% in 2022 and climbed 8.45% in 2025, its largest moves.
• Year by year, Research & Development stood at $36.7 million in 2022, then surged by 32.6% to $48.7 million in 2023, then climbed by 27.35% to $62.0 million in 2024, then climbed by 21.78% to $75.6 million in 2025, then slipped by 0.26% to $75.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $75.4 million in Q1 2026, $75.6 million in Q4 2025, and $69.0 million in Q3 2025.